Sign in
TerminatedPhase 3

Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia

Key facts

Who runs it
Neurocrine Biosciences
Where
Atlanta, Coral Gables, and San Jose, United StatesSee the 3 sites
Trial code
Status
Terminated
Phase
Phase 3
People taking part
8 people enrolled
Started
5 Jan 2023
Ended
8 Nov 2023
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Valbenazine
  • Placebo
Record updated
12 November 2024
Why it stopped
Study ATS3020 was closed due to business reasons. Neurocrine Biosciences will continue to conduct study ATS3019 (NCT05110157). There were no unexpected safety findings for this compound that motivated the decision.

Who can take part

Age
13 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Medically confirmed diagnosis of schizophrenia
  • Participant is receiving a stable regimen of background antipsychotic medication
  • Plasma levels for at least 1 of the participant's antipsychotic medications must be detectable by an available assay
  • Participant is an outpatient with stable symptomatology
  • Participant must have an adult informant (for example, a family member, relative, partner, social worker, caseworker, residential facility staff, or nurse)

Who cannot take part

  • Prior (within 6 months of Screening) or concomitant use of any vesicular monoamine transporter 2 (VMAT2) inhibitor (that is, valbenazine, reserpine, tetrabenazine, deutetrabenazine); or a history of intolerance to VMAT2 inhibitors
  • Has a history of treatment resistant schizophrenia
  • Have a clinically significant unstable medical condition in the judgement of the investigator or any laboratory value outside the normal range that is considered by the investigator to be clinically significant at the screening visit

Where in United States

  • Atlanta, GeorgiaHospital not named in the registry
  • Coral Gables, FloridaHospital not named in the registry
  • San Jose, CaliforniaHospital not named in the registry

About the trial

What the trial wants to find out

This primary objective for this study is to evaluate the effect of adjunctive valbenazine versus placebo on symptoms of schizophrenia in participants who have inadequate response to antipsychotic treatment.

The 2 groups in the trial

  • ValbenazineTreatment being tested

    Valbenazine once daily

  • PlaceboPlacebo, for comparison

    Placebo once daily

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects With Schizophrenia
Record updated
12 November 2024